- Home
- GHY vs LRMR Comparison
GHY vs LRMR Comparison
Compare GHY & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GHY | LRMR |
|---|---|---|
| Founded | 2012 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 472.3M | 455.8M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | GHY | LRMR |
|---|---|---|
| Price | $11.27 | $3.94 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $16.50 |
| AVG Volume (30 Days) | 131.6K | ★ 857.9K |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | ★ 10.58% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,816.14 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.25 | $2.72 |
| 52 Week High | $13.33 | $6.42 |
Technical Indicators
Market Signals| Indicator | GHY | LRMR |
|---|---|---|
| Relative Strength Index (RSI) | 26.50 | 44.77 |
| Support Level | $11.25 | $3.57 |
| Resistance Level | $12.04 | $4.21 |
| Average True Range (ATR) | 0.09 | 0.19 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 1.16 | 20.39 |
Price Performance
Historical ComparisonAbout GHY PGIM Global High Yield Fund Inc.
PGIM Global High Yield Fund, Inc is a diversified, closed-end management investment company. The fund's investment objective is to provide a high level of current income. The fund seeks to provide a high level of current income by investing in higher-rated, below-investment-grade fixed income instruments of issuers located around the world, including emerging markets.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.